(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of 359.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Iterum Therapeutics's revenue in 2025 is $390,000.On average, 4 Wall Street analysts forecast ITRM's revenue for 2025 to be $172,298,984, with the lowest ITRM revenue forecast at $41,385,540, and the highest ITRM revenue forecast at $310,391,553. On average, 4 Wall Street analysts forecast ITRM's revenue for 2026 to be $504,861,362, with the lowest ITRM revenue forecast at $452,812,710, and the highest ITRM revenue forecast at $554,270,630.
In 2027, ITRM is forecast to generate $2,226,161,999 in revenue, with the lowest revenue forecast at $1,194,532,388 and the highest revenue forecast at $3,303,452,952.